MSC Manufacturing for Academic Clinical Trials: From a Clinical-Grade to a Full GMP-Compliant Process

MSC Manufacturing for Academic Clinical Trials: From a Clinical-Grade to a Full GMP-Compliant Process

Following European regulation 1394/2007, mesenchymal stromal cell (MSCs) have become an advanced therapy medicinal product (ATMP) that must be produced following the good manufacturing practice (GMP) standards. We describe the upgrade of our existing clinical-grade MSC manufacturing process to obtai...

Full description

Bibliographic Details
Main Authors:	Chantal Lechanteur, Alexandra Briquet, Virginie Bettonville, Etienne Baudoux, Yves Beguin
Format:	Article
Language:	English
Published:	MDPI AG 2021-05-01
Series:	Cells
Subjects:	cell therapy MSC GMP ATMP manufacturing mesenchymal stromal cells
Online Access:	https://www.mdpi.com/2073-4409/10/6/1320

Similar Items

Immunomodulatory performance of GMP-compliant, clinical-grade mesenchymal stromal cells from four different sources
by: Mandana Kazem Arki, et al.
Published: (2024-01-01)

From Vial to Vein: Crucial Gaps in Mesenchymal Stromal Cell Clinical Trial Reporting
by: Danielle M. Wiese, et al.
Published: (2022-04-01)

Upgrading Monocytes Therapy for Critical Limb Ischemia Patient Treatment: Pre-Clinical and GMP-Validation Aspects
by: Giulio Rusconi, et al.
Published: (2022-10-01)

More Human BM-MSC With Similar Subpopulation Composition and Functional Characteristics Can Be Produced With a GMP-Compatible Fabric Filter System Compared to Density Gradient Technique
by: Gabriele Spohn, et al.
Published: (2021-03-01)

Retrospective Analysis of Autologous Chondrocyte-Based Cytotherapy Production for Clinical Use: GMP Process-Based Manufacturing Optimization in a Swiss University Hospital
by: Virginie Philippe, et al.
Published: (2022-03-01)

Mesenchymal stromal/stem cell (MSC)-derived exosomes in clinical trials
by: Ahmed Lotfy, et al.
Published: (2023-04-01)

Microbiological Aspects of Pharmaceutical Manufacturing of Adipose-Derived Stem Cell-Based Medicinal Products
by: Ilona Szabłowska-Gadomska, et al.
Published: (2023-02-01)

Cell-free DNA measurement of three genomes after allogeneic MSC therapy in kidney transplant recipients indicates early cell death of infused MSC
by: Geertje J. Dreyer, et al.
Published: (2023-11-01)

Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial
by: Céline Grégoire, et al.
Published: (2022-07-01)

ATMP development and pre-GMP environment in academia: a safety net for early cell and gene therapy development and manufacturing
by: D.N. Silva, et al.
Published: (2022-12-01)

Optimization of Mesenchymal Stromal Cell (MSC) Manufacturing Processes for a Better Therapeutic Outcome
by: Maria Eugenia Fernández-Santos, et al.
Published: (2022-06-01)

Basics of advanced therapy medicinal product development in academic pharma and the role of a GMP simulation unit
by: I. Johanna, et al.
Published: (2023-12-01)

The Role of MSC in Wound Healing, Scarring and Regeneration
by: Raquel Guillamat-Prats
Published: (2021-07-01)

When Origin Matters: Properties of Mesenchymal Stromal Cells From Different Sources for Clinical Translation in Kidney Disease
by: Sandra Calcat-i-Cervera, et al.
Published: (2021-09-01)

Human Neural Stem Cell-Based Drug Product: Clinical and Nonclinical Characterization
by: Daniela Celeste Profico, et al.
Published: (2022-11-01)

Non-clinical assessment of safety, biodistribution and tumorigenicity of human mesenchymal stromal cells
by: Claudia Thäte, et al.
Published: (2021-01-01)

MSC in Tendon and Joint Disease: The Context-Sensitive Link Between Targets and Therapeutic Mechanisms
by: Susanne Pauline Roth, et al.
Published: (2022-04-01)

Research and therapy with induced pluripotent stem cells (iPSCs): social, legal, and ethical considerations
by: Sharif Moradi, et al.
Published: (2019-11-01)

Optimization of the Production Process of Clinical-Grade Human Salivary Gland Organoid-Derived Cell Therapy for the Treatment of Radiation-Induced Xerostomia in Head and Neck Cancer
by: Jacoba van Zanten, et al.
Published: (2024-03-01)

Xeno-free protocol for GMP-compliant manufacturing of human fetal pancreas-derived mesenchymal stem cells
by: Zahra Jabbarpour, et al.
Published: (2022-06-01)

Enhancing Immunomodulatory Function of Mesenchymal Stromal Cells by Hydrogel Encapsulation
by: Hui-Yun Cheng, et al.
Published: (2024-01-01)

iPSC-derived mesenchymal stem cells attenuate cerebral ischemia-reperfusion injury by inhibiting inflammatory signaling and oxidative stress
by: Masafumi Arakawa, et al.
Published: (2023-09-01)

Development and Validation of a Fully GMP-Compliant Process for Manufacturing Stromal Vascular Fraction: A Cost-Effective Alternative to Automated Methods
by: Pauline François, et al.
Published: (2020-09-01)

Quality assessment of a serum and xenofree medium for the expansion of human GMP-grade mesenchymal stromal cells
by: Clotilde Aussel, et al.
Published: (2022-05-01)

Process development and validation of expanded regulatory T cells for prospective applications: an example of manufacturing a personalized advanced therapy medicinal product
by: Cristiana Lavazza, et al.
Published: (2022-01-01)

Cell therapy medicinal product regulatory framework in Europe and its application for MSC based therapy development
by: Janis eAncans
Published: (2012-08-01)

Editorial: Translating NK cell scientific research to clinical product manufacturing
by: Evelyn Ullrich, et al.
Published: (2023-08-01)

Effectiveness and safety of mesenchymal stem/stromal cell for radiation-induced hyposalivation and xerostomia in previous head and neck cancer patients (MESRIX-III): a study protocol for a single-centre, double-blinded, randomised, placebo-controlled, phase II study
by: Kathrine Kronberg Jakobsen, et al.
Published: (2023-09-01)

Editorial: Current Progress in Mesenchymal Stem/Stromal Cell Research
by: Lindolfo da Silva Meirelles, et al.
Published: (2021-02-01)

From Single Batch to Mass Production–Automated Platform Design Concept for a Phase II Clinical Trial Tissue Engineered Cartilage Product
by: Sebastian Haeusner, et al.
Published: (2021-08-01)

Mesenchymal Stem or Stromal Cells from Amnion and Umbilical Cord Tissue and Their Potential for Clinical Applications
by: Heinz Redl, et al.
Published: (2012-11-01)

Acceleration of Translational Mesenchymal Stromal Cell Therapy Through Consistent Quality GMP Manufacturing
by: Premkumar Jayaraman, et al.
Published: (2021-04-01)

MSC-EV therapy for bone/cartilage diseases
by: Joe Kodama, et al.
Published: (2022-12-01)

Automated image analysis detects aging in clinical-grade mesenchymal stromal cell cultures
by: S. Oja, et al.
Published: (2018-01-01)

Standard toxicity study of clinical-grade allogeneic human bone marrow-derived clonal mesenchymal stromal cells
by: Behnoosh Tayebi, et al.
Published: (2022-05-01)

Process data of allogeneic ex vivo-expanded ABCB5+ mesenchymal stromal cells for human use: off-the-shelf GMP-manufactured donor-independent ATMP
by: Seda Ballikaya, et al.
Published: (2020-11-01)

Apoptotic MSCs and MSC-Derived Apoptotic Bodies as New Therapeutic Tools
by: Irina V. Kholodenko, et al.
Published: (2022-10-01)

Editorial: Mesenchymal Stromal Cells: Preclinical and Clinical Challenges
by: Joan Oliva, et al.
Published: (2022-07-01)

Mesenchymal stromal cells for osteonecrosis
by: S. Elgaz, et al.
Published: (2020-10-01)

Long-Term Results of a Phase I/II Clinical Trial of Autologous Mesenchymal Stem Cell Therapy for Femoral Head Osteonecrosis
by: Juan F. Blanco, et al.
Published: (2023-03-01)